multiple sclerosis, ms, neurology, consortium, sclerosis, healthcare, multidisciplinary
Contact Us | Print Page | Sign In | Register
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 1 of 11
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

CMSC Industry News for MS (INforMS)
Monday, November 11, 2019   (0 Comments - view/add)
In Memoriam: Alan Mandel »
Our dear friend and colleague Alan Mandel passed away early Monday morning, November 4, 2019. He fought hard in his battle...
Monday, October 7, 2019
CMSC INforMS: Kessler scientists receive grant to study exercise benefits in multiple sclerosis »
Consortium of Multiple Sclerosis Centers awards grant to Drs. John DeLuca and Helen Genova to study the effects of differe...
Tuesday, September 17, 2019
CMSC INforMS: EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in RMS »
- EVOLUTION RMS 1 and 2 pivotal Phase III trials will investigate the efficacy and safety of evobrutinib in relapsing mult...
Thursday, September 12, 2019
CMSC INforMS: Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data »
Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatm...
Wednesday, September 11, 2019
CMSC INforMS: Genentech’s Satralizumab Significantly Reduced Relapse Risk »
Genentech’s Satralizumab Significantly Reduced Relapse Risk in Second Positive Phase III Study for Neuromyelitis Optica Sp...
Tuesday, September 10, 2019
CMSC INforMS: Janet Brown Obituary »
  Janet Brown ( December 30, 1964 - September 08, 2019 ) Ms. Janet Marie Brown, MSN, FNP-BC, MSCN, age 5...
Monday, September 9, 2019
CMSC INforMS: Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data »
Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding of Disease Progression in Multiple...
Saturday, September 7, 2019
CMSC INforMS: Dr Daniel Kantor Highlights MS Treatments and What Is in the Pipeline »
The field of treatments for multiple sclerosis (MS) has grown quickly in the last 30 years, but the next new class of ther...
Wednesday, September 4, 2019
CMSC INforMS: MS Relationships Improved by Togetherness and Communication, Study Suggests »
Relationships between multiple sclerosis patients and their intimate partners were enhanced when the couple worked toget...
Tuesday, September 3, 2019
CMSC INforMS: Press Release - Genetech to present Piviotal Data at ECTRIMS »
Genentech to Present Pivotal Data for Satralizumab in Neuromyelitis Optica Spectrum Disorder and Six-Year Ocrevus (Ocreliz...
Thursday, August 29, 2019
CMSC INforMS: Social cognition, mood and fatigue in multiple sclerosis »
Study by MS research team links deficits in social cognition with fatigue, depressive symptomatology, and anxiety Da...
Saturday, August 24, 2019
CMSC INforMS: The Genetic and Environmental Factors That Can Cause Multiple Sclerosis »
Researchers say genetic makeup is a factor, but so are smoking, obesity, vitamin D, and viral infections. A combinatio...
Wednesday, August 7, 2019
CMSC INforMS: Rutgers Health Leading Program to Support MS Children »
Rutgers Health is leading the Pediatric Multiple Sclerosis and Demyelinating Diseases Program , the only program in the...
Thursday, July 18, 2019
CMSC INforMS: Dr. Anne Cross Discusses Strides In Multiple Sclerosis Research, Recent Award »
Years ago, when many multiple sclerosis researchers believed that a type of immune cell known as a T-cell was the cause of...
Tuesday, July 16, 2019
CMSC INforMS: EMD Serono’s Embracing Carers Launches ‘Time Counts’ to Raise 1M Minutes of Support »
●   ‘Time Counts’ launches as a social media-led video series asking individuals to collectively give 1 million mi...
Friday, June 28, 2019   (0 Comments - view/add)
CMSC INforMS: Alexion’s Soliris gets new, and lucrative, rare disease indication »
June 28, 2019   (This news originally appeared in PharmaPhorum Website at https://phar...
Tuesday, June 25, 2019
CMSC INforMS: Kessler researchers explore social cognitive deficits in progressive MS »
Study by MS research team finds evidence for differential effects of progressive MS on cognitive and affective Theory of M...
Monday, June 24, 2019
CMSC INforMS: CMSC, MS Non-Profits and Polar Products recognizes over 20 years of progress »
  CMSC, MS Non-Profits and Polar Products recognizes over 20 years of progress in the holistic approach to MS sympto...
Saturday, June 22, 2019
CMSC INforMS: June Halper Outlines the Biggest Management Challenges in Multiple Sclerosis »
The biggest clinical challenges that we have in treating multiple sclerosis are 2-fold, explained June Halper, MSN, APN-C,...
Saturday, June 22, 2019
CMSC INforMS: Billings Clinic hosts its first Multiple Sclerosis Health and Well-Being Symposium »
The Billings Clinic hosted its first Multiple Sclerosis Health and Well-Being Symposium. It was a day-long educational sem...
Thursday, June 13, 2019
CMSC INforMS: Study Moves Closer to Identifying Cause of Multiple Sclerosis »
A study by the University of British Columbia made a scientific advance that researchers hope will lead to the development...
Thursday, June 13, 2019
CMSC INforMS: DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making »
A clinical trial based at the Cleveland Clinic and the University of Nottingham , U.K., is recruiting patients with re...
Wednesday, May 15, 2019
CMSC INforMS: UCLA researchers work to advance treatment targeting source of multiple sclerosis »
UCLA researchers are developing the first multiple sclerosis treatment that could target the cause of the disease, instead...
Wednesday, May 8, 2019
CMSC INforMS: Press Release - Genentech Presenting New Ocrevus (Ocrelizumab) Data at AAN Meeting »
Genentech to Present New OCREVUS (ocrelizumab) Data Analyses Showing Significant Reduction of Disability Progression in Re...
Thursday, May 2, 2019
CMSC INforMS: MSAA Recognizes Ten Years of Artwork from Individuals with Multiple Sclerosis »
Each year, the Multiple Sclerosis Association of America's Art Showcases provide the opportunity for artists with multiple...
Tuesday, April 30, 2019
CMSC INforMS: FDA Approves MAVENCLAD® (Cladribine) Tablets »
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment...
Friday, April 19, 2019
CMSC INforMS: OHSU doctors part of 'breakthrough' research on treating multiple sclerosis »
PORTLAND, Ore. ( KATU ) – They're calling it a potential game-changer. Doctors at Oregon Health and Science Universit...
Monday, April 15, 2019
CMSC INforMS: Anne Cross, Neurologist w/Pioneering Work into B-cells/MS, Awarded John Dystel Prize »
This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS ch...
Friday, March 29, 2019   (0 Comments - view/add)
CMSC INforMS: Novartis gets FDA approval for Mayzent (siponimod), the first oral drug to treat SPMS »
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA)...
Wednesday, March 27, 2019
CMSC INforMS: Novartis receives FDA approval for MAYZENT (siponimod) »
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multip...
Tuesday, March 26, 2019
CMSC INforMS: Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis »
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesi...
Thursday, March 14, 2019
CMSC INforMS: BrainStorm Announces First Patient in Phase 2 Clinical Trial Progressive MS »
BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS Enrollment Announced During MS A...
Tuesday, February 19, 2019
CMSC INforMS: Depression, Psychological Distress Symptoms Affect MS Patients’ Quality of Life »
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view...
Tuesday, December 18, 2018   (0 Comments - view/add)
CMSC INforMS: FDA Accepts BrainStorm’s NurOwn® IND Application for Progressive MS »
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of inn...
Friday, October 12, 2018
CMSC INforMS: Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, »
Positive Late-Breaking Phase II Data Evaluating Investigational Oral Therapy, Evobrutinib in RMS   Fir...

Displaying page 1 of 11
1  |  2  |  3  |  4  |  5  |  6  >   >>   >| 

The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275